Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

BTIG analyst Thomas Shrader maintained a Hold rating on Inmune Bio ( INMB – Research Report) yesterday. The company’s shares closed yesterday at $2.31. Take advantage of TipRanks Premium at 50% off!

The Food and Drug Administration restored a top vaccine regulator to his position at the agency just weeks after firing him. Dr. Vinay Prasad resigned after some of his past comments were highlighted ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novavax, with a price target of $8.00. The company’s shares closed yesterday at $7.58. Elevate ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

A research study from the United States suggests that bird flu could have spread amongst cattle through the air or ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

SHREVEPORT, La. - The U.S. Department of Health and Human Services has announced $500 million in funding cuts to vaccine ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...